Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on bisphosphonates.

Stanley B Cohen1

  • 1Radiant Research, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA. stanleycohen@radiantresearch.com

Current Rheumatology Reports
|January 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

The Journal of rheumatology·2025
Same author

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.

Annals of the rheumatic diseases·2025
Same author

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.

RMD open·2025
Same author

EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Safety profile of JAK inhibitors: a focus on baricitinib.

The Lancet. Rheumatology·2024
Same author

Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.

The Lancet. Rheumatology·2024
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
Same journal

Management of IgG4-Related Disease.

Current rheumatology reports·2026
See all related articles

Bisphosphonates effectively treat osteoporosis by suppressing bone turnover, increasing bone mineral density and strength. Ongoing research explores less frequent administration, combination therapies, and potential roles in bone metastases and osteoarthritis.

Area of Science:

  • Pharmacology and Therapeutics
  • Bone Biology and Metabolism
  • Rheumatology

Background:

  • Bisphosphonates have been a cornerstone therapy for osteoporosis for 15 years.
  • They function by suppressing bone turnover, leading to improved bone mineral content and strength.
  • Nitrogen-containing bisphosphonates have demonstrated efficacy in reducing vertebral and nonvertebral fractures.

Purpose of the Study:

  • To review the established efficacy and evolving applications of bisphosphonates in bone health.
  • To discuss the cellular mechanisms, safety profile, and future therapeutic directions for bisphosphonates.
  • To highlight ongoing research into bisphosphonates for bone metastases and osteoarthritis.

Main Methods:

  • Review of scientific literature and clinical trial data on bisphosphonate therapy.

Related Experiment Videos

  • Analysis of cellular mechanisms of action and clinical outcomes in osteoporosis.
  • Examination of post-marketing surveillance data and ongoing research initiatives.

    • Main Results:

    • Bisphosphonates significantly increase bone mineral content and strength by suppressing bone turnover.
    • Reduced fracture risk (vertebral and nonvertebral) is a key outcome in osteoporosis patients.
    • Long-term safety data (5-10 years) support current use, with ongoing monitoring for rare adverse events.

    Conclusions:

    • Bisphosphonates remain highly effective for osteoporosis management, with established safety and efficacy.
    • Future therapeutic strategies involve less frequent dosing and combination with anabolic agents.
    • Emerging research suggests potential roles in managing bone metastases and osteoarthritis.